Cystic fibrosis treatment methods

Details Cystic fibrosis treatment methods Cystic fibrosis treatment methods

2011-03-22

2011-03-22

Padmanabhan, Sreeni (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S169000, C514S172000, C514S176000, C514S177000, C514S178000, C540S106000, C552S516000, C552S519000, C552S522000

Reexamination Certificate

active

07910571

ABSTRACT:
The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.

REFERENCES:
patent: 2566336 (1951-09-01), Julian et al.
patent: 3001988 (1961-09-01), Nysted
patent: 3137710 (1964-06-01), de Ruggieri et al.
patent: 3153063 (1964-10-01), de Ruggieri et al.
patent: 3155690 (1964-11-01), Cole
patent: 3169093 (1965-02-01), Davis
patent: 3189597 (1965-06-01), MacPhillamy et al.
patent: 4330539 (1982-05-01), Sleigh et al.
patent: 4898694 (1990-02-01), Schwartz et al.
patent: 4908358 (1990-03-01), Schreiber
patent: 5206008 (1993-04-01), Loria
patent: 5387583 (1995-02-01), Loria
patent: 5461042 (1995-10-01), Loria
patent: 5506223 (1996-04-01), Lardy et al.
patent: 5585371 (1996-12-01), Lardy
patent: 5635496 (1997-06-01), Daynes et al.
patent: 5686438 (1997-11-01), Daynes et al.
patent: 5811418 (1998-09-01), Daynes et al.
patent: 7396827 (2008-07-01), Ahlem et al.
patent: 7462610 (2008-12-01), Lardy et al.
patent: 7482334 (2009-01-01), Frincke et al.
patent: 7524835 (2009-04-01), Frincke
patent: 7547687 (2009-06-01), Frincke et al.
patent: 2006/0073099 (2006-04-01), Frincke
patent: 2007/0077201 (2007-04-01), Reading et al.
patent: 2007/0129282 (2007-06-01), Ahlem
patent: 2007/0213309 (2007-09-01), Reading et al.
patent: 2007/0265236 (2007-11-01), Reading et al.
patent: 2008/0058301 (2008-03-01), Lardy
patent: 2008/0085873 (2008-04-01), Reading et al.
patent: 2008/0176823 (2008-07-01), Lardy
Arth, G., et al, Steroidal androgen biosynthesis inhibitors,J. Med. Chem., 14(8):675-679 (1971).
Davis, M., et al, Steroid Amines. Part II. 17α-aminoandrostane derivatives,J. Chem. Soc., 1698-1700 (1966).
Flouret, G., et al, 17-aminocylamido-5-androsten-3β-ols,J. Med. Chem., 11:880-882 (1968).
Hewett, C., et al, Amino-steroids. Part IV. 16β-morpholino-17-oxo- and 17β-morpholino-16-oxo-5α-androstanes,J. Chem. Soc., 1880-1883 (1969).
Hussain, A., et al, Testosterone 17β-N, N-dimenthylglycinate hydrochloride: A prodrug with a potential for nasal delivery of testosterone,J. Pharmaceutical Sciences, 91:785-789 (2002).
Irmscher, K., et al, Cholesterol analogues with oxa and oxa-aza side chain a novel class of inhibitors of cholesterol biosynthesis,Steroids, 7(6):557-576 (1966).
Johnson, K., et al, Solution kinetics of a water soluble hydrocortisone prodrug: Hydrocortisone-21-lysinate,J. Pharmaceutical Sciences, 74(1):87-89 (1985).
Jones, J., et al, Steroids and steroidases. 10. Studies on some potentially antitumor active androstane compounds containing C-17 nitrogen mustard functions,J. Med. Chem., 14:(9) 827-833 (1971).
Kabara, J., et al, Structure-function activity of azasterols and nitrogen-containing steroids,Lipids, 11(10):755-762 (1976).
Mokotoff, M., et al, Peptidyl aminosteroids as potential new antiarrhythmic agents,Steroids, 55:399-404 (1990).
Pettit, G., et al, Structural biochemistry. IV. 3β-hydroxy-17β-(L-prolyl) amino-androst-5-ene1-3,Canadian J. Chem., 45:502-507 (1967).
Pettit, R., et al, Antimicrobial and cancer cell growth inhibitory activities of 3β-acetoxy-17β-(L-prolyl)amino-5α-androstanein vitro, International J. Antimicrob. Agents, 15:299-304 (2000).
Robinson, C., et al, the synthesis of 17α-amino-5-androsten-3β-ol; N.M.R. spectra of 17-substituted androstanes,Steroids, 6(5):509-518 (1965).
Yagishita, K, Studies on antimicrobial activities of aminosteroids—II,Bull Coll Agr&Vet Med, Nihon Univ, 28:8-17 (1971).
Zheng, G, et al, Tricarbocyanine cholesteryl laureates labeled LDL: New near infrared fluorescent probes (NIRFs) for monitoring tumors and gene therapy of familial hypercholesterolemia,Bioorganic&Med. Chem. Letters, 12:1485-1488 (2002).
U.S. Appl. No. 11/549,598, filed Oct. 13, 2006, Reading et al.

Affiliated with

Also associated with

Rating

Cystic fibrosis treatment methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cystic fibrosis treatment methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cystic fibrosis treatment methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2685793